Ergomed PLC (LON:ERGO)‘s stock had its “buy” rating reaffirmed by analysts at Stifel Nicolaus in a note issued to investors on Monday, Analyst Ratings.Net reports. They presently have a GBX 281 ($4.00) price objective on the stock. Stifel Nicolaus’ price objective suggests a potential upside of 67.26% from the stock’s previous close.

Separately, N+1 Singer reduced their price target on Ergomed PLC from GBX 290 ($4.13) to GBX 281 ($4.00) and set a “buy” rating for the company in a research report on Wednesday, December 16th.

Ergomed PLC (LON:ERGO) opened at 167.0000 on Monday. The company’s market cap is GBX 48.01 million. The company’s 50-day moving average is GBX 168.34 and its 200-day moving average is GBX 170.41. Ergomed PLC has a 12 month low of GBX 155.00 and a 12 month high of GBX 187.00.

Ergomed PLC is a United Kingdom-based provider of drug development services to the pharmaceutical industry. The Company’s therapeutic focus is on onology, neurology and immunology and the development of orphan drugs. Ergomed Plc manages clinical development from Phase I through to late phase programs. The Company operates in two segments: The services business and the co-development business. The clinical development services offered by the Company include study management, site management, study physician support, safety services, regulatory and quality management, clinical data management and biostatistics, and medical writing. It has planned, managed, monitored, and reported clinical trials with a range of technologies that include small molecule drugs, monoclonal antibodies, tri-functional antibodies, soluble receptors, cancer vaccines and immunotherapy, radioactive agents, and photodynamic therapies. The Company also has co-development deals with other companies.

Receive News & Ratings for Ergomed PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ergomed PLC and related companies with MarketBeat.com's FREE daily email newsletter.